These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 11900401

  • 1. Advances in lipid-lowering therapy in atherosclerosis.
    Davignon J.
    Adv Exp Med Biol; 2001; 498():49-58. PubMed ID: 11900401
    [Abstract] [Full Text] [Related]

  • 2. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J.
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [Abstract] [Full Text] [Related]

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 4. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Oct; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 5. HDL-C: role as a risk modifier.
    Barter P.
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [Abstract] [Full Text] [Related]

  • 6. [Fibrates].
    Yamada N.
    Nihon Rinsho; 2002 May; 60(5):962-7. PubMed ID: 12030000
    [Abstract] [Full Text] [Related]

  • 7. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH, Bachenheimer BS.
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [Abstract] [Full Text] [Related]

  • 8. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D, Velkeniers B, Duquet W, Betz W.
    Int J Cardiol; 2005 May 25; 101(2):231-5. PubMed ID: 15882669
    [Abstract] [Full Text] [Related]

  • 9. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep 25; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 10. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Sep 25; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L, Respondek W, Białobrzeska-Paluszkiewicz J, Grzybowska B, Jakóbisiak-Ostasz B, Stolarska I.
    Pol Merkur Lekarski; 2003 Jul 25; 15(85):42-6. PubMed ID: 14593958
    [Abstract] [Full Text] [Related]

  • 12. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM, Croom KF.
    Drugs; 2007 Jul 25; 67(1):121-53. PubMed ID: 17209672
    [Abstract] [Full Text] [Related]

  • 13. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP.
    Am J Cardiol; 2001 Dec 20; 88(12A):30N-36N. PubMed ID: 11788128
    [Abstract] [Full Text] [Related]

  • 14. New lipid lowering drugs and new effects of old drugs.
    Dujovne CA.
    Curr Opin Lipidol; 1997 Dec 20; 8(6):362-8. PubMed ID: 9412777
    [Abstract] [Full Text] [Related]

  • 15. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L, Dani G.
    Orv Hetil; 2016 May 08; 157(19):746-52. PubMed ID: 27133274
    [Abstract] [Full Text] [Related]

  • 16. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov 08; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cardioprotective and other emerging effects of statins.
    Davignon J.
    Int J Clin Pract Suppl; 2004 Oct 08; (143):49-57. PubMed ID: 16035396
    [Abstract] [Full Text] [Related]

  • 20. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á.
    Clin Investig Arterioscler; 2014 Jul 08; 26 Suppl 1():12-6. PubMed ID: 25043541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.